The first generic version of Sabril® (vigabatrin) tablets to enter the US market.
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Sabril®1 (vigabatrin) tablets, 500 mg in the US, the first generic version of Sabril® (vigabatrin) tablets to enter the US market.
1 Sabril® is a registered trademark of Lundbeck.